Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria (2010)~* At least 2 documented clinical attacks within the last 2 years prior to screening or one clinical attack in the years prior to screening (but not within 30 days prior to screening)~* Neurologic stability for greater than or equal to (\>=) 30 days prior to both screening and baseline~* Expanded Disability Status Scale (EDSS) score 0 to 5.5 inclusive~Exclusion Criteria:~* Primary progressive multiple sclerosis~* Disease duration of more than 10 years in participants with EDSS less than or equal to (\<=) 2.0 at screening~* Contraindications for MRI~* Known presence of other neurological disorders which may mimic multiple sclerosis~* Pregnancy or lactation~* Requirement for chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study~* History of or currently active primary or secondary immunodeficiency~* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies~* Active infection, or history of or known presence of recurrent or chronic infection (e.g., hepatitis B or C, human immunodeficiency virus \[HIV\], syphilis, tuberculosis)~* History of progressive multifocal leukoencephalopathy~* Contraindications to or intolerance of oral or iv corticosteroids~* Contraindications to Rebif or incompatibility with Rebif use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Interferon beta-1a 44 mcg SC (Type: ACTIVE_COMPARATOR): Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
- Ocrelizumab (Type: EXPERIMENTAL): Ocrelizumab 600 mg intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.

Based on this trial design, predict the completion outcome and termination type (if applicable).